"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Head and Neck Cancer
DRUG: Pebrolizumab + QUADSHOT Radiotherapy
Tumor Response Rate, up to 2 years|Health-Related Quality of Life Questionnaire, up to 2 years
Overall Survival, up to 2 years|Progression Free Survival, 6 months|Progression Free Survival, 12 months|Incidence of post treatment toxicities, up to 2 years|Duration of Response, up to 2 years
During this study, patients will receive infusions of pembrolizumab with radiotherapy (palliative QUADSHOT regimen). The patient will receive treatment of pembrolizumab once every 3 weeks and palliative "QUAD SHOT" radiotherapy every 4 weeks. These 28 day period of time is called a cycle. The cycle will be repeated 3 times. Each cycle is numbered in order. The patient will be treated for up to 3 cycles followed by pembrolizumab single drug until unacceptable toxicity or tumor progression.

The patient will also complete a survey.

Total duration of the study is up to two years.